London, United Kingdom
Concr, founded in 2018, is a pioneering techbio company that operates at the intersection of biopharma, biotechnology, and machine learning. Headquartered in the United Kingdom, Concr leverages its unique FarrSight® Bayesian Platform to enhance predictive modeling, providing valuable insights into the efficacy of cancer treatments.
The firm's slogan, "Predict cancer treatment benefit for every patient using multimodal data," emphasizes its ability to offer personalized predictions for cancer therapy responses. By using digital twin simulations derived from multimodal data, Concr enhances the accuracy of predictions even in early-stage trials and for rare cancers—an area where conventional models often fall short.
Concr has built a robust portfolio of collaborations with clients including Roche, Debiopharm, and academic institutions like The University of Queensland. Its investor roster includes notable names like University of Cambridge Enterprise and Cambridge Angels. The recent Innovate UK grant further underlines its credibility and potential to revolutionize treatment decision-making.
